AU · rank #9 · 2026-10-21
DIM
PARIS · EUR · $23.48B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.692 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 3 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $237.29 | +10.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +30.56% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +44.9% |
| 52w high | $225.00 |
| Market cap (USD) | $23.48B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Sartorius Stedim Biotech supplies recurring single-use bioprocessing consumables and equipment for biologics manufacturing, with H1 2026 sales up 6.4% organically and EBITDA margins holding above 31%.
Rationale
The name screens well for analyst_upside because consensus is constructive despite limited visible revisions: 10.4% upside to target, a 4.5/5 average analyst rating, 80% revision agreement, and improving momentum alongside stable growth and margin execution.
Material risks
- 1Equipment demand is still below consumables and delayed orders could push a meaningful share of revenue into 2027–2028, which can slow the upside case if the recovery stalls.
- 2Competitive pressure from Cytiva, Thermo Fisher and Merck can compress pricing in single-use bioprocessing, while U.S. tariff compensation could trim revenue by up to EUR35 million.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.